Opinion: A settlement agreement between and Federal Trade commission and Express Scripts may prove more transformative than any single pricing overhaul because it has restructured the rebate-driven ...

Express Scripts Holding, a pharmacy benefit manager that negotiates drug prices for many health plans, will launch a formulary with lower list price drugs in an effort to reduce reliance on rebates ...

Advocates for lower drug prices say a federal lawsuit filed this month against St Louis-based Express Scripts and two other companies could result in more affordable medicine for patients. The Federal ...

The Federal Trade Commission said it has reached a settlement with Express Scripts, resolving an earlier lawsuit that alleged the pharmacy benefit manager artificially inflated insulin drug prices.

Praluent has a list price of more than $14,000 a year. However, Express Scripts customers will be able to receive the drug for $4,500 to $6,600 annually after discounts and rebates, Express Scripts ...

Wells Fargo is the most recent corporation to get sued, as alleged by former employees, for inadequately overseeing the price workers were forced to pay for prescription drug prices. In a class action ...

The Federal Trade Commission (FTC) may be nearing settlements with the remaining two pharmacy benefit managers involved in a lawsuit over insulin pricing. | The Federal Trade Commission may be nearing ...

Pharmacy benefit managers (PBMs) have used market leverage to demand rebates, which can lead drug manufacturers to increase sticker prices.

Alain Sherter is a senior managing editor with CBS News. He covers business, economics, money and workplace issues for CBS MoneyWatch. Federal regulators are accusing the country's three largest ...

Reforming the prescription system could lead to major savings for patients, with one report putting the number as high as $100 billion annually.